Arcellx Analyst Ratings
Arcellx Analyst Ratings
Arcellx Analyst Ratings
Truist Financial Reaffirms Their Buy Rating on Arcellx Inc (ACLX)
Buy Rating for Arcellx Inc. on Promising CAR-T Cell Therapy Trials and Strategic Market Positioning
Arcellx Analyst Ratings
Arcellx Analyst Ratings
Buy Rating Affirmed for Arcellx Inc on Robust IMMagine-3 Study Prospects and Efficient Manufacturing
Buy Rating Justified for Arcellx Inc. Amidst Progress in Anito-cel's Clinical Development and Regulatory Milestones
Barclays Reaffirms Their Buy Rating on Arcellx Inc (ACLX)
Buy Rating for Arcellx Inc: Strategic Positioning and Promising Clinical Trials Fuel Positive Outlook
Buy Rating and $81 Price Target for Arcellx Inc. Amidst Strong Market Potential and Strategic Gilead Partnership
Arcellx Analyst Ratings
Buy Rating Backed by Potential Regulatory Tailwinds for Arcellx's CAR-T Therapy
Arcellx Analyst Ratings
Optimizing Investment Decisions: Unveiling the Buy Rating for Arcellx Inc.
Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX) and Adaptive Biotechnologies (ADPT)
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Arcellx Inc (ACLX) and AdaptHealth (AHCO)
Arcellx Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Arcellx Inc (ACLX) and Exact Sciences (EXAS)